Nurix Therapeutics Investor Relations Material
Latest events
Study Update
Nurix Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nurix Therapeutics Inc
Access all reports
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule and cell therapies. These therapies are designed to treat cancer and inflammatory diseases by modulating cellular protein levels. Nurix leverages its proprietary DELigase platform, which involves the use of E3 ligases within the ubiquitin-proteasome system, to either decrease or increase protein levels selectively. The company’s drug development strategy includes both targeted protein degraders and ligase inhibitors, addressing unmet medical needs in hematology-oncology, immuno-oncology, and inflammation. The company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
NRIX
Country
🇺🇸 United States